Now available LUNSUMIO VELO™

LUNSUMIO VELO™ (mosunetuzumab-axgb) injection, for subcutaneous use is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Please see full prescribing information here.